Jaguar Health (NASDAQ:
JAGX) announced on April 13, 2026, plans to integrate AI platforms to enhance development, commercialization, and healthcare delivery of crofelemer for intestinal failure (IF) in adult and pediatric patients, including microvillus inclusion disease (MVID).
An investigator-sponsored MVID program demonstrated up to 37% reduction in parenteral support needs.
AI could enable personalized treatment regimens, link genetics, histopathology, and disease progression, and support real-world evidence for faster drug development.
The company is pursuing FDA Breakthrough Therapy designation and non-dilutive funding to accelerate approval.
Short bowel syndrome market, including IF, is projected to reach $8 billion by 2033.
Quotes from CSO Pravin Chaturvedi highlight AI's role in efficient development for ultrarare diseases like MVID; CEO Lisa Conte emphasizes demonstrating effectiveness for faster commercialization.